Thursday 15 October 2026
Export IVVD’s income statement to Excel — free account
Invivyd, Inc.
IVVD Healthcare Biotechnology
Invivyd, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $53.4 million, up 110.5% from fiscal 2024. In the quarter to June 2026, revenue grew 21.2%, EPS fell 16.7% and free cash flow fell 226.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
0.67
0.06
+9.84%
Follow IVVD
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 5.57 | 1.42 | 0.98 | 0.40 | 0.36 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 78.82 | 12.11 | 4.71 | 5.20 | 3.07 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | 103 | 86 | 95 | 100 | 122 | ||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.25 | 0.44 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 25 | 53 | ||||
| Gross margin, % | — | — | — | — | — | 0.00 | 0.00 | — | 93.63 | 92.99 | |||||
| EBT | — | — | — | — | (65) | (227) | (241) | (199) | (170) | (52) | |||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (669.42) | (98.25) | |||||
| Net income | — | 0 | — | — | (65) | (227) | (241) | (199) | (170) | (52) | |||||
| Depreciation | — | — | — | — | — | 1 | (2) | 1 | 3 | 2 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.21 | 0.31 | ||||
| Earnings | — | — | — | — | (18.10) | (5.32) | (2.23) | (1.81) | (1.43) | (0.30) | |||||
| Cash flow | — | — | — | — | (4.04) | (4.33) | (2.03) | (1.58) | (1.44) | (0.34) | |||||
| Capex | — | — | — | — | 0.00 | 0.00 | (0.02) | (0.01) | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | — | (4.04) | (4.34) | (2.05) | (1.59) | (1.44) | (0.34) | |||||
| Book value | — | — | — | — | (18.08) | 13.09 | 3.29 | 1.62 | 0.57 | 1.40 | |||||
| Shares, m | — | — | — | — | 4 | 43 | 108 | 110 | 119 | 172 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | — | — | — | 0.00 | 7.96 | |||||
| P/B | — | — | — | — | — | — | — | — | 0.77 | 1.76 | |||||
| EV/Sales | — | — | — | — | — | — | — | — | 0.00 | 3.72 | |||||
| EV/FCF | — | — | — | — | — | — | — | — | 0.10 | (3.41) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | (15) | (185) | (220) | (173) | (170) | (58) | ||||
| Capex | — | — | — | — | — | 0 | (2) | (1) | 0 | 0 | |||||
| Free cash flow | — | — | — | — | (15) | (185) | (222) | (174) | (171) | (58) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 104 | 555 | 352 | 175 | 39 | 213 | ||||
| Total debt | — | — | — | — | — | — | 4 | — | — | — | |||||
| Net debt | — | — | — | — | (115) | (591) | (372) | (201) | (69) | (227) | |||||
| Shareholders’ equity | — | — | — | — | (65) | 558 | 356 | 177 | 68 | 242 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | (111.29) | (61.50) | (48.11) | (64.88) | (94.75) | (25.83) | ||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (233.82) | |||||
| ROE | — | — | — | — | (26.51) | (92.05) | (52.81) | (74.48) | (138.71) | (33.96) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Invivyd, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| PRQR ProQR Therapeutics N.V. | $196.1M | — (loss-making) | — (loss-making) | +135.03% (above 0%: growing) | n/m | −1.06% (below 0%: shrinking) | 100.00% | (100.72%) | Compare |
| LYEL Lyell Immunopharma, Inc. | $195.8M | — (loss-making) | — (loss-making) | −50.00% (below 0%: shrinking) | n/m | +1.31% (above 0%: growing) | 100.00% | (1,183,425.00%) | Compare |
| RNAC Cartesian Therapeutics, Inc. | $191.8M | — (loss-making) | — (loss-making) | −92.91% (below 0%: shrinking) | −7.84% (below 0%: shrinking) | −6.15% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| ACOG Alpha Cognition Inc. | $191.7M | — (loss-making) | — | +267.56% (above 0%: growing) | n/m | −109.25% (below 0%: shrinking) | 94.80% | (127.29%) | Compare |
| IVVD Invivyd, Inc. | $190.4M | — (loss-making) | — (loss-making) | +21.20% (above 0%: growing) | n/m | −226.89% (below 0%: shrinking) | 91.09% | (320.76%) | |
| ELDN Eledon Pharmaceuticals, Inc. | $190.2M | — (loss-making) | — | — | n/m | −28.02% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CGEN Compugen Ltd. | $187.6M | 5.5× | — (loss-making) | +107.00% (above 0%: growing) | n/m | −155.42% (below 0%: shrinking) | (3.54%) | (339.62%) | Compare |
| UPB Upstream Bio, Inc. | $187.3M | — (loss-making) | — (loss-making) | −17.50% (below 0%: shrinking) | n/m | +9.33% (above 0%: growing) | 100.00% | (5,480.98%) | Compare |
| SION Sionna Therapeutics, Inc. | $185.0M | — (loss-making) | — | — | n/m | −22.40% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $190.9M | — | — | +44.75% | — | −14.27% | 100.00% | (114.00%) |
Invivyd, Inc. (IVVD) key facts
- Strength: Invivyd, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $53.4 million, up 110.5% from fiscal 2024.
- Invivyd, Inc. (IVVD) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 15, 2026, IVVD traded at $0.67, a market capitalization of $190.4 million.
- Return on equity was −34.0% and debt-to-equity 0.00.
- Its Altman Z-score is 2.85 (grey zone) for fiscal 2025.
Invivyd, Inc. (IVVD) Latest News
No news at this impact. Lower the threshold for more.